Solving the Unsolvable
Redefining drug discovery at the molecular level
By combining the technology and data engine of Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab, we created the only end-to-end condensate drug discovery platform built on molecular insights.
Our differentiated molecular platform…
Through our one-of-a-kind technology, we unite droplet microfluidics and state-of-the art cellular imaging for novel drug discovery.
…delivers unique data…
We reveal the impact of chemical matter on condensate systems at the molecular level.
…and powers drug discovery.
Our pioneering engine optimizes chemical matter using machine learning and artificial intelligence.
Latest News
Transition Bio, Inc. and Voyager Therapeutics jointly announced a drug discovery collaboration targeting TDP-43 for ALS and FTD.
Transition Bio presented results from its lead small-molecule inhibitor program targeting YTHDC1 highlighting robust efficacy in MYC-driven cancers, both as a single agent and in combination with standard-of-care therapies.
Transition Bio, Inc., a microfluidics- driven drug discovery platform company using biophysical…
